Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2023

Genmab — Januar 2023

Planlagt Fastgjort Låst Flyttet Genmab
644 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #553

    Rybrevant "
    we have the potential for an interim analysis of the Mariposa study, which is the study of Rybrevant plus lazertinib in front-line non-small cell lung cancer with EGFR mutations in this study versus Tagrisso. And this is an important study for us. And also, we have the potential clinical data from the Papillon study, which is in front-line non-small cell lung cancer in combination with chemotherapy. So, those are important ones in non-small cell lung cancer."

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #554

      If anyone had told me 2 years ago that the genmabbers would be disappointed with a >$2bn quarterly revenue number for Dara, i would have told him he was crazy 😉

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #555

        last february, the first Genmab guidance for the year actually was USD 7.3 – 8.0 billion.

        1 Reply Last reply
        0
        • SolsenS Offline
          SolsenS Offline
          Solsen
          wrote on sidst redigeret af
          #556

          Meget opmuntrende bemærkninger fra JNJ omkring de stoffer Genmab har i JNJ portefølje. Det skal nok blive til mange penge for Genmabs aktionærer. Tak EL !

          1 Reply Last reply
          0
          • D Offline
            D Offline
            deleted-user
            wrote on sidst redigeret af
            #557

            Mornings. Its difficult to disagree that point of view

            1 Reply Last reply
            0
            • J Offline
              J Offline
              JKY_VH
              wrote on sidst redigeret af
              #558

              Tak EL

              1 Reply Last reply
              0
              • P Offline
                P Offline
                ProinvestorNEWS
                wrote on sidst redigeret af
                #559

                3 Reasons Why Johnson & Johnson Stock Could Rebound After a Bad Start in 2023 https://www.proinvestor.com/investornyt/931259/3-reasons-why-johnson-amp-johnson-stock-could-rebound-after-a-bad-start-in-2023

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #560

                  from Scancell: Genmab [] has accelerated one of our antibodies into development - I take that as that they have identified one and started working seriously on it https://www.scancell.co.uk/Data/Sites/1/media/publications/rns/interim-report-31-october-2022.pdf

                  1 Reply Last reply
                  0
                  • BulderB Offline
                    BulderB Offline
                    Bulder
                    wrote on sidst redigeret af
                    #561

                    Sikken dårlig dag det er i dag 😞

                    1 Reply Last reply
                    0
                    • P Offline
                      P Offline
                      Pensionisten
                      wrote on sidst redigeret af
                      #562

                      En såkaldt kollektiv afklapsning hele vejen rundt 😞

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        Pensionisten
                        wrote on sidst redigeret af
                        #563

                        Jeg forstår så ikke helt, hvorfor C25 skal have så store klø i.f.t. resterende lande i Europa.

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #564

                          Sundhed faldt i US i går. Det fortsatte i DK i dag i C25, hvor sektoren med især Novo fylder meget. Læg hertil det aktiespecifikke fald i f.eks. Maersk og Netcompany.

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            Pensionisten
                            wrote on sidst redigeret af
                            #565

                            Det er korrekt, @Helge. Og du hygger dig vel, lige idag, med dine grønne laks 😉

                            1 Reply Last reply
                            0
                            • P Offline
                              P Offline
                              ProinvestorNEWS
                              wrote on sidst redigeret af
                              #566

                              Onsdagens aktier: Svag prognose kostede Netcompany dyrt https://www.proinvestor.com/investornyt/931480/onsdagens-aktier-svag-prognose-kostede-netcompany-dyrt

                              1 Reply Last reply
                              0
                              • BulderB Offline
                                BulderB Offline
                                Bulder
                                wrote on sidst redigeret af
                                #567

                                Rebound i morgen? US rettede sig og endte i nul. NBI inklusive.

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #568

                                  Godmorgen 🙂

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Stroka
                                    wrote on sidst redigeret af
                                    #569

                                    God morgen 🙂

                                    1 Reply Last reply
                                    0
                                    • J Offline
                                      J Offline
                                      JKY_VH
                                      wrote on sidst redigeret af
                                      #570

                                      Det kan vi da håbe Bulder og god morgen;-)

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #571

                                        JNJ raised Darzalex list price with 4.5% this januari. (that is on top of an extra raise last september
                                        of 4.3%)

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #572

                                          Teprotumumab for the treatment of thyroid eye disease https://www.tandfonline.com/doi/abs/10.1080/14712598.2023.2172328?src=&journalCode=iebt20

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper